Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
InhaleRx Limited ( (AU:IRX) ) just unveiled an announcement.
InhaleRx Limited has commenced fully funded manufacturing of its IRX-211 product for a Phase 2 trial targeting Breakthrough Cancer Pain, following shareholder approval to allot Rights to directors in lieu of fees. The company has secured a funding facility of up to $38.5 million to accelerate the development of its products, which are expected to address critical gaps in treatment options and offer significant economic opportunities for shareholders.
More about InhaleRx Limited
InhaleRx Limited is an Australian clinical-stage drug development company specializing in the development of rapid onset, inhaled therapies aimed at addressing unmet medical needs in the pain management and mental health sectors. The company is focused on securing U.S. FDA approval for its products through rapid and cost-effective regulatory pathways, targeting significant economic opportunities in carefully selected clinical indications.
Average Trading Volume: 318,939
Technical Sentiment Signal: Buy
Current Market Cap: A$8.54M
For a thorough assessment of IRX stock, go to TipRanks’ Stock Analysis page.